"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."

Margaret Mead
Review article
peer-reviewed

Retracted: Hypersexuality Addiction and Withdrawal: Phenomenology, Neurogenetics and Epigenetics



Abstract

Hypersexuality is now part of the DSM-V and has been defined as abnormally increased sexual activity. Epidemiological and clinical studies have shown that this non-paraphilic condition consists of "excessive" sexual behaviors and disorders accompanied by personal distress and social and medical morbidity. Hypersexual disorder is conceptualized as primarily a non- paraphilic sexual desire disorder with impulsivity. Pathophysiological perspectives include dysregulation of sexual arousal and desire, sexual impulsivity, sexual addiction, and sexual compulsivity. The nucleus accumbens, situated within the ventral striatum, mediates the reinforcing effects of drugs of abuse, such as cocaine, alcohol, nicotine, and food as well as music. Indeed, it is believed that this structure mandates behaviors elicited by incentive stimuli. These behaviors include natural rewards like feeding, drinking, sexual behavior, and exploratory locomotion. An essential rule of positive reinforcement is that motor responses will increase in magnitude and vigor if followed by a rewarding event. Here, we are hypothesizing that there is a common mechanism of action (MOA) for the powerful effects drugs, music, food, and sex have on human motivation. The human drive for the three necessary motivational behaviors "hunger, thirst, and sex" may all have common molecular genetic antecedents that, if impaired, lead to aberrant behaviors. We hypothesize that based on a plethora of scientific support hypersexual activity is indeed like drugs, food, and music that activate brain mesolimbic reward circuitry. Moreover, dopaminergic gene and possibly other candidate neurotransmitter-related gene polymorphisms affect both hedonic and anhedonic behavioral outcomes. There is little known about both the genetics and epigenetics of hypersexuality in the current literature. However, we anticipate that future studies based on assessments with clinical instruments combined with genotyping of sex addicts will provide evidence for specific clustering of sexual typologies with polymorphic associations. The authors are also encouraging both clinical and academic scientists to embark on research using neuroimaging tools to examine natural dopaminergic agonistic agents targeting specific gene polymorphisms to "normalize" hyper- or hyposexual response.



Want to read more?

Create a free account to continue reading this article.

Already a member? Login.



Review article
peer-reviewed

Hypersexuality Addiction and Withdrawal: Phenomenology, Neurogenetics and Epigenetics


Author Information

Kenneth Blum Corresponding Author

Department of Psychiatry, McKnight Brain Institute, University of Florida

Rajendra D. Badgaiyan

Department of Psychiatry, and Laboratory of Advanced Radiochemistry, University of Minnesota School of Medicine

Mark S. Gold

Departments of Psychiatry & Behavioral Sciences, Keck School of Medicine of USC, Los Angeles, CA, USA


Ethics Statement and Conflict of Interest Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: Dr. Blum is the co-recipient of a grant from the Life Extension Foundation , Ft. Lauderdale , Fl., USA to Path Foundation, NYC, USA. Dr. Badgaiyan is supported by NIH 1R01NS07884. Financial relationships: Kenneth Blum declare(s) personal fees, a patent and royalties from Dominion Diagnostic LLC. Licence agreement for genetic testing. Kenneth Blum declare(s) non-financial support, royalties and stock/stock options from RDSS LLC. License agreement for Synaptamine . Kenneth Blum declare(s) personal fees, non-financial support and a patent from Victory Nutrition International ,LLC. license agreement for Brain Reward. Kenneth Blum declare(s) non-financial support and a patent from Malibu Beach Recovery Center . Consultant. Kenneth Blum
declare(s) personal fees, non-financial support and a patent from Rivermend Health. Member Scientific Advisory Board. Mark S. Gold declare(s) non-financial support and a patent from Rivermend Health. Chairman Scientific Advisory Board. Intellectual property info: US patent no. 6,132,724; 6,955,873 issued. US PATENT APPLICATION 11/250,355;
PCT /US2009/048074;
PROVISIONAL 62,08,173. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

The authors appreciate the expert edits and artwork design of Margaret A. Madigan.


Review article
peer-reviewed

Hypersexuality Addiction and Withdrawal: Phenomenology, Neurogenetics and Epigenetics


Figures etc.

Share
Review article
peer-reviewed

Retracted: Hypersexuality Addiction and Withdrawal: Phenomenology, Neurogenetics and Epigenetics

Kenneth Blum">Kenneth Blum , Rajendra D. Badgaiyan">Rajendra D. Badgaiyan, Mark S. Gold">Mark S. Gold

  • Author Information
    Kenneth Blum Corresponding Author

    Department of Psychiatry, McKnight Brain Institute, University of Florida

    Rajendra D. Badgaiyan

    Department of Psychiatry, and Laboratory of Advanced Radiochemistry, University of Minnesota School of Medicine

    Mark S. Gold

    Departments of Psychiatry & Behavioral Sciences, Keck School of Medicine of USC, Los Angeles, CA, USA


    Ethics Statement and Conflict of Interest Disclosures

    Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: Dr. Blum is the co-recipient of a grant from the Life Extension Foundation , Ft. Lauderdale , Fl., USA to Path Foundation, NYC, USA. Dr. Badgaiyan is supported by NIH 1R01NS07884. Financial relationships: Kenneth Blum declare(s) personal fees, a patent and royalties from Dominion Diagnostic LLC. Licence agreement for genetic testing. Kenneth Blum declare(s) non-financial support, royalties and stock/stock options from RDSS LLC. License agreement for Synaptamine . Kenneth Blum declare(s) personal fees, non-financial support and a patent from Victory Nutrition International ,LLC. license agreement for Brain Reward. Kenneth Blum declare(s) non-financial support and a patent from Malibu Beach Recovery Center . Consultant. Kenneth Blum
    declare(s) personal fees, non-financial support and a patent from Rivermend Health. Member Scientific Advisory Board. Mark S. Gold declare(s) non-financial support and a patent from Rivermend Health. Chairman Scientific Advisory Board. Intellectual property info: US patent no. 6,132,724; 6,955,873 issued. US PATENT APPLICATION 11/250,355;
    PCT /US2009/048074;
    PROVISIONAL 62,08,173. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

    Acknowledgements

    The authors appreciate the expert edits and artwork design of Margaret A. Madigan.


    Article Information

    Published: July 27, 2015

    DOI

    10.7759/cureus.290

    Cite this article as:

    Blum K, Badgaiyan R D, Gold M S (July 27, 2015) Hypersexuality Addiction and Withdrawal: Phenomenology, Neurogenetics and Epigenetics. Cureus 7(7): e290. doi:10.7759/cureus.290

    Publication history

    Received by Cureus: July 23, 2015
    Peer review began: July 24, 2015
    Peer review concluded: July 27, 2015
    Published: July 27, 2015

    Copyright

    © Copyright 2015
    Blum et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 3.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

    License

    This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Hypersexuality is now part of the DSM-V and has been defined as abnormally increased sexual activity. Epidemiological and clinical studies have shown that this non-paraphilic condition consists of "excessive" sexual behaviors and disorders accompanied by personal distress and social and medical morbidity. Hypersexual disorder is conceptualized as primarily a non- paraphilic sexual desire disorder with impulsivity. Pathophysiological perspectives include dysregulation of sexual arousal and desire, sexual impulsivity, sexual addiction, and sexual compulsivity. The nucleus accumbens, situated within the ventral striatum, mediates the reinforcing effects of drugs of abuse, such as cocaine, alcohol, nicotine, and food as well as music. Indeed, it is believed that this structure mandates behaviors elicited by incentive stimuli. These behaviors include natural rewards like feeding, drinking, sexual behavior, and exploratory locomotion. An essential rule of positive reinforcement is that motor responses will increase in magnitude and vigor if followed by a rewarding event. Here, we are hypothesizing that there is a common mechanism of action (MOA) for the powerful effects drugs, music, food, and sex have on human motivation. The human drive for the three necessary motivational behaviors "hunger, thirst, and sex" may all have common molecular genetic antecedents that, if impaired, lead to aberrant behaviors. We hypothesize that based on a plethora of scientific support hypersexual activity is indeed like drugs, food, and music that activate brain mesolimbic reward circuitry. Moreover, dopaminergic gene and possibly other candidate neurotransmitter-related gene polymorphisms affect both hedonic and anhedonic behavioral outcomes. There is little known about both the genetics and epigenetics of hypersexuality in the current literature. However, we anticipate that future studies based on assessments with clinical instruments combined with genotyping of sex addicts will provide evidence for specific clustering of sexual typologies with polymorphic associations. The authors are also encouraging both clinical and academic scientists to embark on research using neuroimaging tools to examine natural dopaminergic agonistic agents targeting specific gene polymorphisms to "normalize" hyper- or hyposexual response.



Want to read more?

Create a free account to continue reading this article.

Already a member? Login.



Kenneth Blum

Department of Psychiatry, McKnight Brain Institute, University of Florida

For correspondence:
drd2gene@gmail.com

Rajendra D. Badgaiyan, M.D., Professor

Department of Psychiatry, and Laboratory of Advanced Radiochemistry, University of Minnesota School of Medicine

Mark S. Gold

Departments of Psychiatry & Behavioral Sciences, Keck School of Medicine of USC, Los Angeles, CA, USA

Kenneth Blum

Department of Psychiatry, McKnight Brain Institute, University of Florida

For correspondence:
drd2gene@gmail.com

Rajendra D. Badgaiyan, M.D., Professor

Department of Psychiatry, and Laboratory of Advanced Radiochemistry, University of Minnesota School of Medicine

Mark S. Gold

Departments of Psychiatry & Behavioral Sciences, Keck School of Medicine of USC, Los Angeles, CA, USA